drugset / Trial / NCT05593770

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

NCT05593770

Phase 2/3 Terminated 28 enrolled NEAT ID Foundation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

Timeline

Start
2022-10-27
Primary completion
2023-12-14
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 100 mg Oral
Subject Fostamatinib Small molecule 150 mg Oral

Indications